Research programme: oncolytic virus antineoplastics - Papyrus Therapeutics/Targovax
Latest Information Update: 28 Mar 2025
At a glance
- Originator Papyrus Therapeutics; Targovax
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Immunostimulants; Receptor protein-tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Solid-tumours in Norway (Parenteral)
- 28 Mar 2025 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 09 Feb 2021 Targovax enters into a research collaboration agreement with Papyrus Therapeutics to develop antineoplastics